Cancer

FDA Approves New Immunotherapy for Endometrial Cancer

13 days ago   |   By Medscape

The accelerated approval for dostarlimab is for use in patients with recurrent or advanced endometrial cancers with deficient mismatch repair .
FDA Approvals
Read more ...

 

FDA approves Jemperli for endometrial cancer subset

FDA approves Jemperli for endometrial cancer subset

13 days ago   |   By Healio

The FDA granted accelerated approval to dostarlimab-gxly for treatment of certain women with endometrial cancer.
The approval applies to use of the agent by women with mismatch repair-deficient recurrent or advanced disease that progressed on or after a platinum-containing regimen.
Dostarlimab-gxly is a PD-1 antagonist.
The FDA - which had granted priority review and breakthrough therapy designations to dostarlimab-gxly for this indication - based the approval on results of a cohort in the multicenter, open-label GARNET trial.
The efficacy population
Read more ...

 

PD-1 Inhibitor Approved for dMMR Endometrial Cancer

PD-1 Inhibitor Approved for dMMR Endometrial Cancer

13 days ago   |   By MedPageToday

The FDA granted accelerated approval to the monoclonal antibody dostarlimab for recurrent/advanced endometrial cancer associated with deficient mismatch repair .
The approval pertains to patients previously...
Read more ...

 

FDA approves immunotherapy for treating patients with dMMR endometrial cancer

13 days ago   |   By News Medical

Today, the U.S. Food and Drug Administration granted accelerated approval to Jemperli for treating patients with recurrent or advanced endometrial cancer that has progressed on or following prior treatment with a platinum-containing chemotherapy and whose cancers have a specific genetic feature known as dMMR (which contain abnormalities that affect the proper repair of DNA inside the cell), as determined by an FDA-approved test.
Read more ...

 


Search by Tags

   Cancer      Hematology-Oncology      News Alert      Food      Drugs  


The Latest: Indonesia bans traveling home for Eid al-Fitr

Indonesia is prohibiting travel during the popular homecoming period to celebrate Eid al-Fitr Read more ...

NZ suspends quarantine-free travel to and from Sydney

The decision was made following the detection of two community cases in Sydney. Read more ...

Apple's AirTag trackers made it frighteningly easy to ‘stalk' me

Apple's new AirTags, $45 wireless devices that help you locate things, work well. Frighteningly well. Read more ...

List manager Ned Guy quits Collingwood after tumultuous off-season

The man who oversaw Collingwood's salary cap firesale and list overhaul last year, Ned Guy, has quit the club. Read more ...

Johns brothers won't be ‘laying out witches' hats' for Samoa coach Parish

Matthew Johns has rejected calls from the Samoan coach to be his assistant as the battle to coach the Pacific nation intensifies. Read more ...

Cutting gas use for heating and cooking is not the way to net zero

Customers should be informed about new energy options and be empowered to adopt them, rather than restricting their choices by simply taking options away. Read more ...

Young athletes must not be ill-treated in the rush for gold medals

A report into gymnastics in Australia shows the risks in the win-at-all-costs approach to sports. Read more ...

Promoting the Language of ‘Reframing Aging' During Older Americans Month

With the theme of Older Americans Month being “Communities of Strength,” the organization Changing the Narrative is taking the opportunity to promote positive and constructive... Read more ...

Report: Growing with Age - Unlocking the Power of the Multigenerational...

Inclusion in the workplace, including older workers, can strengthen business resilience to provide a competitive advantage, according to a report and toolkit from AARP... Read more ...

Benefits of drug research are not being shared equitably among study...

A Yale-led study reveals that new medicines and vaccines approved for use in the United States are often unavailable in countries that hosted their clinical trials, suggesting... Read more ...